Description
Sidana Super Drive
Sidana Super Drive is a combination product identified as containing sildenafil and dapoxetine. Based on the verified ingredients, it combines a phosphodiesterase type 5 inhibitor used for erectile dysfunction with a short-acting selective serotonin reuptake inhibitor used for premature ejaculation. The clinical evidence for this combination is limited, but published studies have examined dapoxetine plus sildenafil in men with both conditions.
Active Ingredient and Medicine Class
Sildenafil is a phosphodiesterase-5 (PDE5) inhibitor. It increases the effect of nitric oxide in penile tissue by helping preserve cyclic GMP, which supports blood flow needed for an erection. Official prescribing information describes sildenafil as a PDE5 inhibitor used for erectile dysfunction and certain other approved indications depending on formulation.
Dapoxetine is a selective serotonin reuptake inhibitor (SSRI) developed for premature ejaculation. EMA describes it as a short-acting SSRI that increases serotonin signalling in the nervous system.
Established Medical Uses
Sildenafil is an established treatment for erectile dysfunction. Dapoxetine is an established treatment for premature ejaculation in adult men in jurisdictions where it is authorised. Combination use has been studied in men who have both erectile dysfunction and premature ejaculation, but the evidence base is much smaller than for either ingredient alone.
How It Works
Sildenafil helps relax smooth muscle in the penis during sexual stimulation, which can improve the ability to obtain and maintain an erection. Dapoxetine acts on serotonin pathways involved in ejaculatory control and may delay ejaculation. The combination is intended to address both erection difficulty and early ejaculation when both are present.
Important Safety Information
Sildenafil must not be used with nitrates, and it is also contraindicated with guanylate cyclase stimulators such as riociguat because of the risk of severe hypotension. Important precautions include cardiovascular disease, low blood pressure, recent stroke or heart attack, severe liver impairment, and certain eye conditions. Dapoxetine should be avoided with other serotonergic medicines and with monoamine oxidase inhibitors because of the risk of serotonin syndrome. Clinically important interactions are also described with strong CYP3A4 inhibitors and some alpha-blockers and antihypertensives.
Possible Side Effects
Reported adverse effects with sildenafil include headache, flushing, dyspepsia, nasal congestion, dizziness, and visual disturbance; rare but serious reactions include prolonged erection, sudden vision loss, and sudden hearing loss. Dapoxetine is commonly associated with nausea, dizziness, headache, diarrhoea, and insomnia; more serious risks include fainting and serotonin syndrome. Combination studies have reported mostly mild, transient adverse events such as headache, palpitations, and flushing.
Scientific Evidence
Clinical studies have explored dapoxetine with sildenafil in men who have both premature ejaculation and erectile dysfunction. The DAP-SPEED study reported improvements in intravaginal ejaculatory latency time and patient-reported outcomes over a short treatment period, with mostly non-serious adverse events. Earlier randomized work also evaluated dapoxetine together with PDE5 inhibitor therapy and found symptomatic benefit in selected patients, but the overall evidence remains limited compared with the evidence for each medicine separately.
Medical Information Notice
This summary is for educational purposes only and reflects sources available at the time of review. It does not replace the official patient leaflet, prescribing information, or assessment by a qualified healthcare professional.
Medical Sources
- European Medicines Agency — Priligy referral
- DailyMed — Sildenafil tablets, prescribing information
- Tuken M, et al. — Efficacy and safety of dapoxetine/sildenafil combination tablets in the treatment of men with premature ejaculation and concomitant erectile dysfunction-DAP-SPEED Study — International Journal of Impotence Research, 2019
